Longeveron’s Big Move with Stem Cell Therapy | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded20 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070905

Show notes

Longeveron is on the verge of a breakthrough with its stem cell therapy Laromestrocel, poised to revolutionize treatments for hypoplastic left heart syndrome, Alzheimer’s, and age-related frailty. Upcoming phase two trial data for HLHS in mid-September could redefine the company’s trajectory. Their work has earned them a prestigious XPRIZE HealthSpan finalist spot — the only publicly traded firm to receive it — based on compelling results improving walking distance in frailty patients. Longeveron is also forging strategic partnerships with pharma giants to accelerate commercialization, while preparing for a registrational trial in pediatric dilated cardiomyopathy, approved by the FDA. Despite a modest Q2 revenue and rising expenses leading to a net loss, their cash reserves are projected to last through Q4 2026, positioning them for significant future growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4a6015def14d68e1

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.